High-affinity binding of peptide agonists to the human B1 bradykinin receptor depends on interaction between the peptide N-terminal L-lysine and the fourth extracellular domain of the receptor

Molecular Pharmacology

Volumn 57, Issue 1, 2000, Pages 171-179

  Fathy, Dana B ^a   Kyle, Donald J ^b   Leeb Lundberg, L M Fredrik ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; BRADYKININ RECEPTOR AGONIST;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; HUMAN; HUMAN CELL; INFLAMMATION; LIGAND BINDING; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BINDING, COMPETITIVE; BRADYKININ; CELLS, CULTURED; HUMANS; LYSINE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN CONFORMATION; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; RECOMBINANT FUSION PROTEINS;

EID: 0033976629     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Abd Alla S, Quitterer U, Grigoriev S, Maidhoff A, Haasemann M, Jarnagin K and Müller-Esterl W (1996) Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies. J Biol Chem 271:1748-1755.
2. Alkhatib G, Ahuja SS, Light D, Mummidi S, Berger EA and Ahuja SK (1997) CC chemokine receptor 5-mediated signaling and HIV-1 co-receptor activity share common structural determinants: Critical residues in the third extracellular loop support HIV-1 fusion. J Biol Chem 272:19771-19776.
3. Bhoola KD, Figueroa CD and Worthy K (1992) Bioregulation of kinins: Kallikreins, kininongens, and kininases. Pharmacol Rev 44:1-80.
4. Dray A and Perkins M (1993) Bradykinin and inflammatory pain. Trends Neurosci 16:99-104.
5. Farmer SG, McMillan BA, Meeker SN and Burch RM (1991) Induction of vascular smooth muscle bradykinin B1 receptors in vivo during antigen arthritis. Agents Actions 34:191-193.
6. Fathy DB, Mathis SA, Leeb T and Leeb-Lundberg LMF (1998) A single position in the third transmembrane domains of the human B1 and B2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands. J Biol Chem 273:12210-12218.
7. 281 of AT1 receptor is essential for full agonism. J Biol Chem 270:12846-12850.
8. Furuto-Kato S, Matsumoto A, Kitamura N and Nakanishi S (1985) Primary structures of the mRNAs encoding the rat precursors for bradykinin and T-kinin. Structural relationship of kininogens with major acute phase protein and alpha 1-cysteine proteinase inhibitor. J Biol Chem 260:12054-12059.
9. 195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state. J Biol Chem 273:14380-14386.
10. Herzig MCS and Leeb-Lundberg LMF (1995) The agonist binding site on the bovine bradykinin B2 receptor is adjacent to a sulfhydryl and is differentiated from the antagonist binding site by chemical cross-linking. J Biol Chem 270:20591-20598.
11. 277 in the receptor. J Biol Chem 271: 29746-29751.
12. Hess JF, Borkowski JA, Young GS, Strader CD and Ransom RW (1992) Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 184:260-268.
13. Hess JF, Derrick AW, MacNeil T and Borkowski JA (1996) The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors. Immunopharmacology 33:1-8.
14. Hjorth SA, Schambye HT, Greenlee WJ and Schwartz TW (1994) Identification of peptide binding residues in the extracellular domains of the ATI receptor. J Biol Chem 269:30953-30959.
15. Kyle DJ, Martin JA, Farmer SG and Burch RM (1991) Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem 34:1230-1233.
16. Kyle DJ, Chakravarty S, Sinsko JA and Stormann TM (1994) A proposed model of bradykinin bound to the rat B2 receptor and its utility for drug design. J Med Chem 37:1347-1354.
17. Leeb T, Mathis SA and Leeb-Lundberg LMF (1997) The sixth transmembrane domains of the human B1 and B2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists. J Biol Chem 272:311-317.
18. Marie J, Koch C, Pruneau D, Paquet J-L, Groblewski T, Larguier R, Lombard C, Deslauriers B, Maigret B and Bonnafous JC (1999) Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI. Mol Pharmacol 55:92-101.
19. Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, Ransom RW, Strader CD, Linemeyer DL and Hess JF (1994) Expression cloning of a human B1 bradykinin receptor. J Biol Chem 269:21583-21586.
20. Nardone J and Hogan PJ (1994) Delineation of a region in the B2 bradykinin receptor that is essential for high-affinity agonist binding. Proc Natl Sci Acad USA 91:4417-4421.
21. Ni A, Chai KX, Chao L and Chao J (1998) Molecular cloning and expression of rat bradykinin B1 receptor. Biochim Biophys Acta 1442:177-185.
22. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A and Karnik SS (1995) Tetrazole and carboxylate groups of angiotensin reeptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 270:2284-2289.
23. Novotny EA, Bednar DL, Connolly MA, Connor JR and Stormann TM (1994) Mutation of aspartate residues in the third extracellular loop of the rat B2 bradyinin receptor decreases affinity for bradykinin. Biochem Biophys Res Commun 201: 523-530.
24. Phagoo SB, Poole S and Leeb-Lundberg LMF (1999) Autoregulation of bradykinin receptors: Agonists in the presence of interleukin-1β shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol Pharmacol 56:325-333.
25. Proud D and Kaplan AP (1988) Kinin formation: Mechanisms and role in inflammatory disorders. Annu Rev Immunol 6:49-83.
26. Regoli D and Barabe J (1980) Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1-46.
27. Ryn K, Gilchrist RL, Tung C-S, Ji I and Ji TH (1998) High affinity hormone binding to the extracellular N-terminal exodomain of the follicle-stimulating hormone receptor is critically modulated by exoloop 3. J Biol Chem 273:28953-28958.
28. Schwartz TW, Perlman S, Rosenkilde MM and Hjorth S (1997) How receptor mutagenesis may confirm or confuse receptor classification. Ann New York Acad Sci 812:71-84.
29. 2- and COOH-terminal sequences and susceptibility to various glandular kallikreins. J Biol Chem 265:10030-10035.
30. Tancredi M, Galoppini C, Meini S, Quartara L, Maggi CA and Rovero P (1997) Synthesis and biological activity of new bradykinin pseudopeptide B1 receptor agonists containing alkylic spacers. Bioorg Med Chem Lett 7:2661-2664.
31. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA and Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251.
32. Tropea MM, Munoz CM and Leeb-Lundberg LMF (1992) Bradykinin binding to B2 kinin receptors and stimulation of phosphoinositide turnover and arachidonic acid release in primary cultures of cells from late pregnant rat myometrium. Can J Physiol Pharmacol 70:1360-1371.
33. Varga, EV, Li X, Stropova D, Zalewska T, Landsman RS, Knapp RJ, Malatynska E, Kawai K, Mizusura A, Nagase H, Calderon SN, Rice K, Hruby VJ, Roeske WR and Yamamura HI (1996) The third extracellular loop of the human δ-opioid receptor determines the selectivity of δ-opioid agonists. Mol Pharmacol 50:1619-1624.
34. Wang WW, Shahrestanifar M, Jin J and Howells RD (1995) Studies on μ and δ opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proc Natl Acad Sci USA 92:12436-12440.
35. Yamano Y, Ohyama K, Kikyo M, Sano T, Nakagomi Y, Inoue Y, Nakamura N, Morishima I, Guo D, Hamakubo T and Inagami T (1995) Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). J Biol Chem 270: 14024-14030.